SEARCH:   Advanced

Blood, 27 August 2009, Vol. 114, No. 9, pp. 1729-1735. Prepublished online as a Blood First Edition Paper on June 26, 2009; DOI 10.1182/blood-2009-04-205013. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2009-04-205013v1 114/9/1729    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Kumar, S. Articles by Rajkumar, S. V. PubMed PubMed Citation Articles by Kumar, S. Articles by Rajkumar, S. V. Related Collections Perspectives Transplantation Free Research Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  PERSPECTIVE Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens Shaji Kumar1, Sergio Giralt2, Edward A. Stadtmauer3, Jean L. Harousseau4, Antonio Palumbo5, William Bensinger6, Raymond L. Comenzo7, Suzanne Lentzsch8, Nikhil Munshi9, Ruben Niesvizky10, Jesus San Miguel11, Heinz Ludwig12, Leif Bergsagel1, Joan Blade13, Sagar Lonial14, Kenneth C. Anderson9, Patrizia Tosi15, Pieter Sonneveld16, Orhan Sezer17, David Vesole18, Michele Cavo19, Hermann Einsele20, Paul G. Richardson9, Brian G. M. Durie21, S. Vincent Rajkumar1, on behalf of the International Myeloma Working Group (IMWG) 1 Division of Hematology, Mayo Clinic, Rochester, MN; 2 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston; 3 Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Abramson Cancer Center, Philadelphia; 4 Department of Hematology, Institute de Biologie, Nantes, France; 5 Divisione di Ematologia dell Universita di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette Torino, Italy; 6 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; 7 Department of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, NY; 8 Division of Hematology/Oncology University of Pittsburgh UMPC Cancer Pavilion, PA, 9 Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA; 10 Weill Cornell Medical College, New York, NY; 11 Department of Hematology, Servicio de Hepatología, Hospital Universitario de Salamanca, CIC, IBMCC (USAL-CSIC), Spain; 12 1st Medical Department, Center for Oncology and Hematology, Wilhelminenspital, Wien, Vienna, Austria; 13 Department of Hematology, Hospital Clinic, IDIBAPS, Barcelona, Spain; 14 Department of Hematology & Medical Oncology, Emory University, Atlanta, GA; 15 Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy; 16 Erasmus MC, Department of Hematology, Rotterdam, The Netherlands; 17 Department of Hematology/Oncology, University of Berlin, Berlin, Germany; 18 David Vesole, Division of Hematology/Oncology, Loyola University, Chicago, IL; 19 Institute of Hematology and Medical Oncology Seragnoli, Bologna, Italy; 20 Department of Internal Medicine University of Wurzburg, Wurzburg, Germany; and 21 Aptium Oncology Inc, Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA The past decade has witnessed a paradigm shift in the initial treatment of multiple myeloma with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, leading to improved outcomes. High-dose therapy and autologous stem cell transplantation remains an important therapeutic option for patients with multiple myeloma eligible for the procedure. Before the advent of the novel agents, patients underwent stem cell collection prior to significant alkylating agent exposure, given its potential deleterious effect on stem cell collection. With increasing use of the novel agents in the upfront setting, several reports have emerged raising concerns about their impact on the ability to collect stem cells. An expert panel of the International Myeloma Working Group (IMWG) was convened to examine the implications of these therapies on stem collection in patients with myeloma and to develop recommendations for addressing these issues. Here we summarize the currently available data and present our perspective on the problem and potential options to overcome this problem. Specifically, we recommend early mobilization of stem cells, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents and encourage participation in clinical trials evaluating novel approaches to stem cell mobilization. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020